Abbott Laboratories (ABT) Stock Forecast & Price Target

$117.82

+1.77 (+1.53%)

(As of 10/16/2024 ET)

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 13 Analyst Ratings

Sell
0

Hold
3

Buy
10

Based on 13 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 13 analysts, 3 have given a hold rating, and 10 have given a buy rating for ABT.

Consensus Price Target

$125.54
6.55% Upside

According to the 13 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $125.54. The highest price target for ABT is $143.00, while the lowest price target for ABT is $107.00. The average price target represents a forecasted upside of 6.55% from the current price of $117.82.

ABT Analyst Ratings Over Time

Type	Current Forecast 10/18/23 to 10/17/24	1 Month Ago 9/18/23 to 9/17/24	3 Months Ago 7/20/23 to 7/19/24	1 Year Ago 10/18/22 to 10/18/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	10 Buy rating(s)
Hold	3 Hold rating(s)	2 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$125.54	$121.80	$120.18	$120.47
Forecasted Upside	6.55% Upside	3.11% Upside	17.78% Upside	26.07% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Election warning coming true… (Ad)

If you missed it, my emergency election broadcast is now available - watch it before it's too late.

Click here to watch it now.

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Abbott Laboratories Stock vs. The Competition

Type	Abbott Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.77	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	6.55% Upside	13,463.88% Upside	6.11% Upside
News Sentiment Rating	Positive News See Recent ABT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
10/14/2024	Raymond James 4 of 5 stars	Reiterated Rating	Outperform ➝ Buy	$122.00 ➝ $129.00	+10.28%
10/8/2024	Royal Bank of Canada 4 of 5 stars	Boost Target	Outperform ➝ Outperform	$125.00 ➝ $130.00	+13.33%
10/8/2024	Oppenheimer 3 of 5 stars	Initiated Coverage	Outperform	$130.00	+14.69%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$120.00 ➝ $124.00	+8.87%
9/26/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$120.00 ➝ $120.00	+6.84%
9/19/2024	Piper Sandler Companies Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$131.00	+14.04%
The most serious warning of my career (Ad) With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election. Click here now to grab your seat now.
8/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$119.00 ➝ $127.00	+13.95%
7/30/2024	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$140.00 ➝ $143.00	+37.90%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$121.00	+20.11%
12/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$116.00 ➝ $121.00	+13.70%
10/19/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$130.00 ➝ $118.00	+25.35%
10/19/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$112.00 ➝ $107.00	+13.23%
7/21/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Neutral ➝ Neutral	$110.00 ➝ $115.00	+2.85%
7/21/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
4/20/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform	$132.00 ➝ $133.00	+19.44%
4/20/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight	$118.00 ➝ $122.00	+9.56%
4/17/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$125.00 ➝ $130.00	+25.05%
3/31/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$90.00 ➝ $102.00	+2.95%
3/30/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target		$125.00 ➝ $115.00	+16.61%
1/26/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy	$110.00 ➝ $125.00	+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:22 AM ET.

Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, October 13, 2024. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

Here are some ways that investors could benefit from investing in Abbott Laboratories:

Abbott Laboratories has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
The company has a diversified product portfolio across healthcare segments, reducing risk associated with dependence on a single product.
Abbott Laboratories has a solid track record of dividend payments, providing investors with a reliable income stream.
Recent analyst price targets suggest a positive outlook for the stock, indicating potential for capital appreciation.
With a current stock price of $115.62, Abbott Laboratories offers a stable investment opportunity with room for growth.

Abbott Laboratories
Bear Case

Investors should be bearish about investing in Abbott Laboratories for these reasons:

Abbott Laboratories operates in a highly regulated industry, subject to potential changes in healthcare policies that could impact profitability.
The company faces competition from other healthcare giants, which may limit market share growth and pricing power.
Fluctuations in currency exchange rates could affect Abbott Laboratories' international operations and financial results.
Investors should consider the company's debt-to-equity ratio of 0.33, which may indicate higher financial leverage and associated risks.
While the PEG ratio of 2.86 suggests growth potential, investors should be cautious of potential overvaluation in the stock.

ABT Forecast - Frequently Asked Questions

: According to the research reports of 13 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $125.54, with a high forecast of $143.00 and a low forecast of $107.00.
: 13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ABT shares.
: According to analysts, Abbott Laboratories's stock has a predicted upside of 6.55% based on their 12-month stock forecasts.
: Over the previous 90 days, Abbott Laboratories's stock had 1 downgrade by analysts.
: Abbott Laboratories has been rated by research analysts at Barclays, Citigroup, Edward Jones, Evercore ISI, Jefferies Financial Group, Oppenheimer, Piper Sandler, Piper Sandler Companies, Raymond James, and Royal Bank of Canada in the past 90 days.
: Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.77 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ABT compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Unlock 2024's Top Stock! 🌟 (Ad)

Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.

Get Your Free Report

This page (NYSE:ABT) was last updated on 10/17/2024 by MarketBeat.com Staff

From Our Partners